FDA reclassification proposal could ease approval process for CAD software

The FDA has proposed reclassifying medical image analyzers used in mammography for breast cancer, ultrasound for breast lesions, x-ray for lung nodules and x-ray for dental caries as class II medical devices instead of class III. This proposal would make it easier for medical device manufacturers to gain FDA approval for computer-assisted detection devices that fall under those specific categories.

“If finalized, this order will reclassify these types of devices from class III to class II and reduce regulatory burdens on industry as these types of devices will no longer be required to submit a premarket approval application (PMA) but can instead submit a less burdensome premarket notification (510(k)) before marketing their device,” the FDA stated in the proposed order.

The proposal, which can be read in full here, will be published in the Federal Register on June 4. There will be a 60-day comment period. Electronic or written comments will be accepted and will be made public.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.